Stefan Thottunkal

Mr. Stefan Thottunkal

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
STStefan Thottunkal
Stefan Thottunkal
CSClaire Spahn
Claire Spahn
BWBenjamin Wang
Benjamin Wang
NRNidhi Rohatgi
Nidhi Rohatgi
JHJison Hong
Jison Hong
Latha PalaniappanLatha Palaniappan
Latha Palaniappan
Pharmacogenomics (PGx) has emerged as a powerful tool to personalize drug selection and dosing based on a patient’s genetic profile. However, there are a range of challenges that impede uptake in current clinical practice. For example, clinicians often express frustration with commercially available PGx panel tests, which fail to consistently include all key actionable PGx genes (according to the Clinical Pharmacogenetics Implementation Consortium (CPIC), Food and Drug Administration (FDA) PGx guidelines, or The Dutch Pharmacogenetics Working Group (DPWG) guidelines) and instead are too long with clinically unimportant information (unvalidated genotypes). Additionally, the lack of EMR integration, clinician education and awareness of the benefits of PGx impedes uptake. This paper examines key challenges identified in clinical practice and proposes future directions, focusing on limiting PGx reports to essential data, providing point-of-prescription alerts, and establishing reimbursement pathways that encourage adoption. Future directions include leveraging large language models, integrating point-of-prescription alerts and phenoconversion calculators into the electronic medical record, increasing the genomic diversity of PGx study populations, and streamlining coverage by payers.

1 January 2024 in Western Pacific Surveillance and Response Journal
Verified
Journal Article
Open access
PDF file
APAmy Elizabeth Parry
Amy Elizabeth Parry
SCSai Campbell
Sai Campbell
STStefan Thottunkal
Stefan Thottunkal
PMPartha Pratim Mandal
Partha Pratim Mandal
SSSharon Salmon
Sharon Salmon
Objective: The COVID-19 pandemic challenged the Global Outbreak Alert and Response Network’s (GOARN) mechanism used to rapidly deploy technical support for international responses and highlighted areas that require strengthened capacity within the Network. GOARN’s partners in the World Health Organization’s (WHO) South-East Asia and Western Pacific regions were engaged to explore their levels of preparedness, readiness and ability to respond to international public health emergencies. Methods: Consultative discussions were held and a survey was conducted with GOARN’s partners from the two WHO regions. Discussion topics included partners’ capacity to support and participate in a GOARN deployment, training, research and collaboration. Descriptive and content analyses were conducted. Results: Barriers to engaging in GOARN’s international outbreak response efforts included limited numbers of personnel trained to respond to outbreaks; institutional, financial and administrative hurdles; and limited collaboration opportunities. Partners identified innovative solutions that could strengthen their engagement with deployment, such as financial subsidies, mentorship for less experienced staff, and the ability to provide remote support. Discussion: GOARN plays an important role in enabling WHO to fulfil its international alert and response duties during disease outbreaks and humanitarian crises that have the potential to spark disease outbreaks. Yet without systematic improvement to strengthen national outbreak capacity and regional connectedness, support for international outbreak responses may remain limited. Thus, it is necessary to integrate novel approaches to support international deployments, as identified in this study.

27 March 2025 in Journal of Regulatory Science
Verified
Journal Article
Open access
PDF file
STStefan Thottunkal
Stefan Thottunkal
The new EU Medical Device Regulations (MDR), originally put forth in 2017, aimed to improve medical device safety in light of regulatory failures. However, although the MDR have improved safety requirements, they have inadvertently created barriers for innovation which have disproportionately impacted small and medium-sized enterprises (SMEs) and orphan device manufacturers. This commentary explores the unintended consequences of the EU MDR as a cautionary case study for the U.S. Food and Drug Administration (FDA), emphasizing the need to balance regulations. In particular, this commentary discusses the mechanisms by which increased evidence requirements, extended approval timelines, and increased costs have led to market contraction which threaten patient health. Creative solutions are proposed including provisional approvals, subsidized applications, and international recognition agreements. The implications and precedent set by the MDR are used to forewarn emerging regulations in artificial intelligence-enabled medical devices.

5 August 2025
Verified
Journal Article
Open access
PDF file
HYHUIWEN YU
HUIWEN YU
STStefan Thottunkal
Stefan Thottunkal
BYBernardo Nugroho Yahya
Bernardo Nugroho Yahya
YWYongheng Want
Yongheng Want
TZTao Zhang
Tao Zhang
Mourad KharbachMourad Kharbach
Mourad Kharbach
Artificial intelligence (AI) technology has revolutionized the healthcare industry by enhancing the accuracy, efficiency, cost-effectiveness, and automation of modern biomedical diagnostics. AI algorithms and models such as machine learning (ML), deep learning (DL), natural language processing (NLP), tensor computing, and generative artificial intelligence have made significant progress and are integral in biomedical diagnosis. However, the development of AI in the biomedical field faces challenges related to policy regulation and ethical issues that need to be addressed for continued progress. This article briefly reviews the recent progress of AI technology in biomedical diagnosis and related policy regulation issues. We aim to provide new insights into transforming AI for biomedical diagnosis towards more liable, effective regulation and improve adaptive innovation of enterprises.